Atrion Co. (NASDAQ:ATRI) Chairman Emile A. Battat sold 721 shares of the firm’s stock in a transaction that occurred on Wednesday, May 17th. The shares were sold at an average price of $542.64, for a total value of $391,243.44. Following the completion of the sale, the chairman now owns 152,112 shares in the company, valued at $82,542,055.68. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Shares of Atrion Co. (NASDAQ:ATRI) traded down 0.43% during trading on Friday, hitting $535.30. The stock had a trading volume of 1,559 shares. Atrion Co. has a 52 week low of $385.00 and a 52 week high of $545.25. The stock has a market capitalization of $982.81 million, a price-to-earnings ratio of 32.50 and a beta of 0.89. The stock’s 50 day moving average is $501.29 and its 200 day moving average is $483.65.
Atrion (NASDAQ:ATRI) last posted its quarterly earnings data on Thursday, February 23rd. The medical instruments supplier reported $3.00 earnings per share for the quarter. Atrion had a net margin of 19.61% and a return on equity of 18.54%. The firm had revenue of $33.29 million during the quarter. On average, equities research analysts expect that Atrion Co. will post $9.90 earnings per share for the current fiscal year.
Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/emile-a-battat-sells-721-shares-of-atrion-co-atri-stock/1835990.html
Receive News & Ratings for Atrion Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion Co. and related companies with MarketBeat.com's FREE daily email newsletter.